Direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection and the risk of hepatocellular carcinoma (HCC) recurrence: A protocol for a systematic literature review

First published 18/06/2021

Last updated 23/02/2022

EU PAS number:

EUPAS41657

Study

Finalised

Documents

Study protocol

Initial protocol

DAA_Consortium-IQVIA SLR Protocol - EU PAS

English (6.15 MB - PDF)View document

Study results

Hep C Consortium-IQVIA_DAA for HCV and risk of HCC_Abstract-EU PAS

English (193.5 KB - PDF)View document

Study report

Other information

Secondary tabs